Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.84 HKD | +4.67% |
|
-.--% | +35.54% |
24/05 | Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation | MT |
24/05 | Henlius' EU Marketing Application for Denosumab Biosimilar Accepted and Validated by Regulator | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+35.54% | 1.31B | |
+1.43% | 94.45B | |
-0.66% | 38.9B | |
-13.57% | 32.56B | |
+71.74% | 28.34B | |
-12.73% | 15.98B | |
-2.15% | 13.82B | |
-13.59% | 11.34B | |
+158.88% | 9.81B | |
-52.04% | 9.67B |
- Stock Market
- Equities
- 2696 Stock
- News Shanghai Henlius Biotech, Inc.
- Henlius Biotech Amends License Deals with Palleon for Bifunctional Protein Products